Adenylate Cyclase Deficient Bordetella Strains
AssigneesNational University of Singapore, Institut Pasteur de Lille, Institut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsSylvie Claudette Alonso, Rui Fen, Annabelle Lim, Camille Locht
Life of this patent
Estimating the term…
Abstract
A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.
Claims19
A vaccine comprising a pharmaceutically acceptable carrier and a live attenuated Bordetella strain that has been rendered deficient in functional adenylate cyclase toxin (CyaA), pertussis toxin (PTX), dermonecrotic toxin (DNT), and tracheal cytotoxin (TCT), but retains the ability to colonize a mammalian subject's lungs and induce a protective immune response against Bordetella infection.
The Bordetella strain designated BPAL10.
A method of protecting a mammalian subject from developing pertussis, the method comprising the step of administering to the mammalian subject a vaccine comprising a sufficient amount of a live attenuated Bordetella strain that has been rendered deficient in functional adenylate cyclase toxin (CyaA), pertussis toxin (PTX), dermonecrotic toxin (DNT), and tracheal cytotoxin (TCT) to elicit immune response that prevents the mammalian subject from developing pertussis after exposure to Bordetella pertussis.
Dependencies are inferred from the claim text.